- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04566991
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH) (DISH)
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (DISH)
Aneurysmal subarachnoid hemorrhage (aSAH) has a high incidence of mortality and significant morbidity, with mortality exceeding 30% in the first two days.The initial injury is related to increasing intracranial pressure, cerebral edema, and neuronal injuries associated with the release of iron. Iron has been shown to increase the incidence of cerebral edema, ischemia, and formation of hydrocephalus. Deferoxamine mesylate (DFO), a hydrophilic chelator, creates a stable complex with free iron thus preventing the formation of iron related free radicals.
This trial will evaluate the safety and efficacy of clinical deferoxamine for the treatment of aSAH for patients that are admitted to the hospital at the University of Michigan or Peking University Health Science Center. Eligible participants will be enrolled and randomized to 1 of 2 doses of Deferoxamine or placebo (saline). Information regarding the patients will be collected and followed for up to 6 months post discharge.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Sravanthi Koduri
- Phone Number: 734-647-7960
- Email: skoduri@med.umich.edu
Study Contact Backup
- Name: Aditya Pandey, MD
- Phone Number: 734-615-2763
- Email: adityap@umich.edu
Study Locations
-
-
Beining
-
Beijing, Beining, China
- Not yet recruiting
- Peking University Health Science Center
-
Contact:
- Yining Huang, MD
- Phone Number: +86 10 83572857
- Email: ynhuang@bjmu.edu.cn
-
-
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan
-
Contact:
- Koduri Sravanthi
- Email: skoduri@med.umich.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aneurysmal SAH confirmed with vascular imaging
- Aneurysm treated with endovascular or microsurgical intervention
- Hunt-Hess ≤ 4
- Modified Fisher Grade I-IV
- Glasgow Coma Scale (GCS) ≥ 7 following External Ventricular Drain (EVD) placement if indicated
- First dose of drug can be administered within 24 hours of symptom onset
- Functional independence prior to SAH, Modified Rankin Scale (mRS) ≤ 1
- Informed consent obtained by patient or legal authorized representative (LAR)
Exclusion Criteria:
- Previous hypersensitivity to or treatment with deferoxamine
- Presence of giant aneurysm (>25 mm in size)
- Known severe iron deficiency anemia, Hemoglobin (Hgb) g/dl ≤ 7 or transfusion dependent
- Irreversibly impaired brainstem function
- Abnormal renal function, Serum Creatinine> 2 mg/dL
- Pre-existing severe disability, mRS ≥ 2
- Coagulopathy, including use of anti-platelet or anticoagulant drugs
- Known severe hearing loss
- Patients with significant respiratory disease such as chronic obstructive pulmonary disease, pulmonary fibrosis, or on home oxygen (O2)
- Taking iron supplements containing > 325 mg of ferrous iron
- Pregnancy
- Life expectancy less than 90 days due to co-morbidities
- Concurrent participation in another research protocol for investigation of another experimental therapy, though observational studies are allowed
- Prior history of hepatic dysfunction
- Known cytopenia (platelets < 50,000, Absolute neutrophil count < 500)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Deferoxamine lower dose
Deferoxamine 32 Milligram Per Kilogram (mg/kg)
|
There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 milligram per kilogram per hour (mg/kg/hr). The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose. Patients will be randomized to 32 mg/kg or 48 mg/kg of Deferoxamine.
Other Names:
|
Experimental: Deferoxamine higher dose
Deferoxamine 48 mg/kg
|
There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 milligram per kilogram per hour (mg/kg/hr). The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose. Patients will be randomized to 32 mg/kg or 48 mg/kg of Deferoxamine.
Other Names:
|
Placebo Comparator: Placebo
normal saline
|
There will be 3 doses given to the patients days 1-3.
Dose will be given intravenous with a fixed rate of 7.5 mg/kg/hr.
The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Utility-weighted modified Rankin Scale (UW-mRS) at 6 months
Time Frame: 6 months (after hospital discharge)
|
Overall a Bayesian, longitudinal model will be used, this will be adjusted for baseline expected 6 month mRS using the FRESH score.
At baseline, the expected 6 month UW-mRS (based on prognostic variables such as age and Hunt Hess) will be entered as the first value for the patient.
Therefore, patients with greater severity at baseline, who achieve excellent outcomes will contribute a larger treatment effect.
Similarly, patients with greater severity who have disability, but perform better than expected can still contribute useful information.
|
6 months (after hospital discharge)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Montreal Cognitive Assessment (MOCA)
Time Frame: At discharge from hospital (approximately 3-4 weeks)
|
Montreal cognitive assessment is a rapid sensitive screening tool for assessment of impaired cognitive function.
The main domains of MoCA scale include attention, executive functions, memory, language, attention, naming, orientation, and visual-spatial ability.
The total score is 30 points.
A score of 25 points or less indicated impaired cognitive function.
For patients with less than 12 years of education, one point was added to the total score.
|
At discharge from hospital (approximately 3-4 weeks)
|
Montreal Cognitive Assessment (MOCA)
Time Frame: 6 months (after hospital discharge)
|
Montreal cognitive assessment is a rapid sensitive screening tool for assessment of impaired cognitive function.
The main domains of MoCA scale include attention, executive functions, memory, language, attention, naming, orientation, and visual-spatial ability.
The total score is 30 points.
A score of 25 points or less indicated impaired cognitive function.
For patients with less than 12 years of education, one point was added to the total score.
|
6 months (after hospital discharge)
|
Percentage of patients requiring permanent cerebrospinal fluid (CSF) diversion due to hydrocephalus at 6 months
Time Frame: 6 months
|
6 months
|
|
Partial pressure of oxygen (PaO2) and fraction of inspired oxygen (FiO2) ratio (worst value for each parameter for each day of infusion, and 48 hours after end of infusion)
Time Frame: up to 48 hours after day 3 infusion
|
Worst value for each parameter for each day of infusion, and 48 hours after end of infusion.
|
up to 48 hours after day 3 infusion
|
To estimate the proportion of non-intubated participants at each dose who experience intubation or initiation of non-invasive positive pressure ventilation during the DFO
Time Frame: infusion days 1-3
|
infusion days 1-3
|
|
Incidence of delayed cerebral ischemia/vasospasm
Time Frame: up to 14 days after aSAH
|
This is based on radiographic evidence on computed tomography angiogram and clinical correlation with neurologic exam.
|
up to 14 days after aSAH
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aditya Pandey, MD, University of Michigan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Intracranial Hemorrhages
- Hemorrhage
- Subarachnoid Hemorrhage
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Iron Chelating Agents
- Siderophores
- Deferoxamine
Other Study ID Numbers
- HUM00163868
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aneurysmal Subarachnoid Hemorrhage
-
Medical University InnsbruckRecruitingSubarachnoid Hemorrhage | Subarachnoid Hemorrhage, Aneurysmal | Aneurysmal Subarachnoid Hemorrhage | Vasospasm, CerebralAustria
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedBrain Ischemia | Subarachnoid Hemorrhage | Subarachnoid Hemorrhage, Aneurysmal | Delayed Cerebral Ischemia | Aneurysmal Subarachnoid Hemorrhage | Vasospasm, CerebralMexico
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingSubarachnoid Hemorrhage, Aneurysmal | Subarachnoid Hemorrhage, SpontaneousItaly
-
IRCCS San RaffaeleFondazione Policlinico Universitario Agostino Gemelli IRCCS; Azienda Ospedaliera... and other collaboratorsRecruitingSubarachnoid Hemorrhage, Aneurysmal | Poor Grade Subarachnoid HemorrhageItaly
-
Hackensack Meridian HealthRecruitingStroke | Subarachnoid Hemorrhage, Aneurysmal | Aneurysmal Subarachnoid Hemorrhage | Cerebral Aneurysm | Cerebral Ischemia | Vasospasm, CerebralUnited States
-
University of Texas Southwestern Medical CenterRecruitingSubarachnoid Hemorrhage, AneurysmalUnited States
-
Milton S. Hershey Medical CenterRecruiting
-
Second Affiliated Hospital, School of Medicine,...RecruitingSubarachnoid Hemorrhage, AneurysmalChina
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingAneurysmal Subarachnoid HemorrhageChina
-
Ascension South East MichiganRecruitingAneurysmal Subarachnoid HemorrhageUnited States
Clinical Trials on Deferoxamine
-
Brigham and Women's HospitalDr. Jeffrey Thomas Stroke Shield FoundationTerminatedSubarachnoid HemorrhageUnited States
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalTerminatedAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic SyndromeUnited States
-
Beth Israel Deaconess Medical CenterMedical University of South Carolina; Johns Hopkins University; Massachusetts... and other collaboratorsCompletedIntracerebral HemorrhageUnited States, Canada
-
Novartis PharmaceuticalsCompletedTransfusional Hemosiderosis | Transfusional Iron OverloadTaiwan, Turkey, Egypt, United Kingdom, Thailand, Canada, China, Italy, Cyprus, Lebanon, United Arab Emirates
-
Memorial Sloan Kettering Cancer CenterCenter for Experimental Therapeutics; F.M. KIRBY FOUNDATIONRecruitingLeptomeningeal MetastasesUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHematologic Diseases | Iron Overload | Hemoglobinopathies | Thalassemia | Beta-Thalassemia | Hemochromatosis | Anemia (Iron-Loading)
-
Capital Medical UniversityPeking University First Hospital; Peking University People's Hospital; Beijing... and other collaboratorsUnknownIntracerebral HemorrhageChina
-
Beth Israel Deaconess Medical CenterMedical University of South Carolina; Massachusetts General Hospital; National... and other collaboratorsCompletedIntracerebral HemorrhageUnited States
-
Elliott VichinskyCompletedIron Overload | ThalassemiaUnited States
-
TauTona GroupWithdrawnSickle Cell Disease | Chronic Cutaneous UlcerUnited States